Combined use of erythropoiesis-stimulating agents and transfusion guidelines in NICU infants

Abstract

Red blood cell transfusions from adult donors can be lifesaving for neonates with severe anemia or acute massive hemorrhage but can be associated with specific and significant risks. Infectious transmission, acute lung injury, and circulatory overload are well known risks and are part of blood transfusion informed consent. Less well-described, but more common, are the risks that occur when transfusing the smallest and most immature neonates, those less than 1000 g. Repeated adult red cell transfusions may worsen inflammatory conditions, such as pulmonary inflammation, and they can increase the incidence and severity of retinopathy of prematurity and neurodevelopmental delay. In this review, we will provide an overview of neonatal transfusion stewardship including instituting both non-pharmacological transfusion-avoidance techniques and pharmacologic strategies to reduce transfusion rates. Erythropoiesis-stimulating agents like erythropoietin and darbepoetin further reduce and can eliminate the need for a transfusion. Instituting non-pharmacologic and pharmacologic strategies will increase the number of NICU infants who remain transfusion free, even those born weighing less than 1000 g.